Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS)

Open access
You, Lina, Jiang, Haidong · 2021 · Bioengineered

Abstract

Sepsis is a disease induced by severe systemic inflammation and contributes to multiple acute organic dysfunctions. It is reported that disrupted blood-brain barrier (BBB) integrity is involved in sepsis-associated encephalopathy (SAE), which can be alleviated by repairing the damaged tight junction structure. Cabergoline is a specific dopamine D2 receptor agonist developed to treat Parkinson’s disease and hyperprolactinemia and is reported to exert promising anti-inflammatory properties. The present study aimed to explore the beneficial effect of Cabergoline for the treatment of sepsis. In the animal experiments, mice were separated into 4 groups: sham, LPS (5 mg/kg), Cabergoline (0.1 mg/kg/day), and Cabergoline+LPS. We found that the increased neurological deficits, disrupted BBB integrity, elevated production of inflammatory factors, and declined expression level of zonula occludens-1 (ZO-1) were observed in lipopolysaccharide (LPS)-treated mice, all of which were significantly reversed by the administration of Cabergoline. In the in vitro model, human brain microvascular endothelial cells (HBMECs) were challenged with 1 µg/mL LPS in the presence or absence of Cabergoline (10, 20 μM) for 24 hours. The elevated cell permeability Papp value of fluorescein disodium across the HBMECs monolayer and declined trans-endothelial electrical resistance (TEER) in the LPS-treated HBMECs were significantly alleviated by Cabergoline, accompanied by the upregulation of ZO-1. In addition, wnt1 and β-catenin were found downregulated, which was reversed by Cabergoline. Importantly, the protective benefits of Cabergoline were all abolished by the overexpression of Dickkopf 3 (DKK3). Taken together, our data reveal that Cabergoline possessed a protective effect on BBB integrity against LPS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21655979.2021.1987066

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Molecular structure of Cabergoline
Figure 1. Molecular structure of CabergolineCC BY · PubMed Central
Figure 2. Cabergoline reduces LPS-induced increase in blood–brain barrier permeability in mice brains. Blood–brain permeability was evaluated by intravenous injection sodium fluorescein (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)
Figure 2. Cabergoline reduces LPS-induced increase in blood–brain barrier permeability in mice brains. Blood–brain permeability was evaluated by intravenous injection sodium fluorescein (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)CC BY · PubMed Central
Figure 3. Cabergoline increases expression of ZO-1 in LPS-challenged mice brains. (a) mRNA level of ZO-1; (b) Protein level of ZO-1 determined by immunostaining. Scale bar, 50 μm (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)
Figure 3. Cabergoline increases expression of ZO-1 in LPS-challenged mice brains. (a) mRNA level of ZO-1; (b) Protein level of ZO-1 determined by immunostaining. Scale bar, 50 μm (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)CC BY · PubMed Central
Figure 4. Cabergoline inhibits the production of inflammatory mediators in LPS- challenged mice brain vessels. (a) mRNA level of TNF-α; (b) mRNA of IL-6; (c). Secretion of TNF-α; (d) Secretion of IL-6 (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)
Figure 4. Cabergoline inhibits the production of inflammatory mediators in LPS- challenged mice brain vessels. (a) mRNA level of TNF-α; (b) mRNA of IL-6; (c). Secretion of TNF-α; (d) Secretion of IL-6 (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group, n = 9–10)CC BY · PubMed Central
Figure 5. Cabergoline attenuates HBMECs monolayer permeability induced by LPS in HBMECs. Cells (1x105 cells/well) were seeded onto 24-well trans-well inserts and then challenged with 1 µg/mL LPS for 24 h in the presence and absence of Cabergoline (10, 20 μM). (a) The Cell permeability Papp value of fluorescein disodium across HBMECs monolayer was evaluated. (b) TEER of the integrity of HBMECs monolayer (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)
Figure 5. Cabergoline attenuates HBMECs monolayer permeability induced by LPS in HBMECs. Cells (1x105 cells/well) were seeded onto 24-well trans-well inserts and then challenged with 1 µg/mL LPS for 24 h in the presence and absence of Cabergoline (10, 20 μM). (a) The Cell permeability Papp value of fluorescein disodium across HBMECs monolayer was evaluated. (b) TEER of the integrity of HBMECs monolayer (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)CC BY · PubMed Central
Figure 6. Cabergoline restored the expression of ZO-1 in LPS-challenged HBMECs. Cells were challenged with 1 µg/mL LPS in the presence and absence of Cabergoline (10, 20 μM) for 24 hours. (a) mRNA level of ZO-1; (b) Protein level of ZO-1 (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)
Figure 6. Cabergoline restored the expression of ZO-1 in LPS-challenged HBMECs. Cells were challenged with 1 µg/mL LPS in the presence and absence of Cabergoline (10, 20 μM) for 24 hours. (a) mRNA level of ZO-1; (b) Protein level of ZO-1 (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)CC BY · PubMed Central
Figure 7. Cabergoline reduced the expression of DKK3 in LPS-challenged HBMECs. (a). mRNA level of DKK3; (b). Protein level of DKK3 (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)
Figure 7. Cabergoline reduced the expression of DKK3 in LPS-challenged HBMECs. (a). mRNA level of DKK3; (b). Protein level of DKK3 (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)CC BY · PubMed Central
Figure 8. Cabergoline activated the Wnt/β-catenin pathway in LPS-challenged HBMECs. Protein levels of wnt1 and β-catenin were determined (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)
Figure 8. Cabergoline activated the Wnt/β-catenin pathway in LPS-challenged HBMECs. Protein levels of wnt1 and β-catenin were determined (####, P < 0.001 vs. vehicle group; $, $$, P < 0.05, 0.01 vs. LPS group, n = 5–6)CC BY · PubMed Central
Figure 9. The effects of Cabergoline against LPS-induced HBMECs monolayer permeability are mediated by DKK3. HBMECs were transfected with DKK3-overexpressing adenovirus or vehicle and then challenged with 1 µg/m L LPS h in the presence and absence of Cabergoline (20 μM) for 24. (a) protein level of DKK3 was determined; (b) The Cell permeability Papp value of fluorescein disodium across HBMECs monolayer was evaluated; (c). Protein level of wnt1 and β-catenin; (d) Protein level ZO-1 was determined (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group; ***, P < 0.005 vs. LPS+ Cabergoline group, n = 5–6)
Figure 9. The effects of Cabergoline against LPS-induced HBMECs monolayer permeability are mediated by DKK3. HBMECs were transfected with DKK3-overexpressing adenovirus or vehicle and then challenged with 1 µg/m L LPS h in the presence and absence of Cabergoline (20 μM) for 24. (a) protein level of DKK3 was determined; (b) The Cell permeability Papp value of fluorescein disodium across HBMECs monolayer was evaluated; (c). Protein level of wnt1 and β-catenin; (d) Protein level ZO-1 was determined (####, P < 0.001 vs. vehicle group; $$, P < 0.01 vs. LPS group; ***, P < 0.005 vs. LPS+ Cabergoline group, n = 5–6)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 19

Metadata

Authors
You, L., & Jiang, H.
Affiliations
  • Chongqing Jiulongpo People's Hospital (CN)
  • Chongqing Infectious Disease Medical Center
Corresponding author
Jiang, Haidong
Venue
Bioengineered
Published
2021-01
Volume
12
Issue
1
Pages
8358-8369
ISSN
  • 2165-5979 (ISSN-L)
  • 2165-5987
OpenAlex
W3204568078
Cited by
17
References
46
Citations by year
2026: 2 · 2025: 4 · 2024: 6 · 2023: 3 · 2022: 2
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • Bioengineered (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Chongqing Infectious Disease Medical Center
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
cabergoline, blood-brain barrier integrity, lipopolysaccharide, sepsis-associated encephalopathy, sepsis, tight junctions, zonula occludens-1, brain microvascular endothelial cells, Wnt/β-catenin signaling, Dickkopf-3, dopamine D2 receptor agonist, neuroprotection, transendothelial electrical resistance, brain permeability
MeSH terms
Cabergoline, Animals, Blood-Brain Barrier, Cell Line, Female, Humans, Lipopolysaccharides, Male, Permeability, Molecular Structure, Sepsis, Mice, Wnt Signaling Pathway, Zonula Occludens-1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS). https://app.cochat.ai/papers/10.1080/21655979.2021.1987066
The paper
You, L., & Jiang, H. (2021). Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS). Bioengineered. https://doi.org/10.1080/21655979.2021.1987066

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.